Johnson & Johnson (NYSE:JNJ) Shares Up 0.7%

Johnson & Johnson (NYSE:JNJ)’s share price was up 0.7% during trading on Tuesday . The stock traded as high as $151.08 and last traded at $150.35. Approximately 1,220,305 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 7,227,401 shares. The stock had previously closed at $149.24.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent research reports. The Goldman Sachs Group assumed coverage on Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, July 1st. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and raised their target price for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Morgan Stanley lowered their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research note on Monday, June 17th. Eight analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $174.07.

Johnson & Johnson Trading Up 0.9 %

The business’s 50-day moving average price is $147.95 and its two-hundred day moving average price is $153.41. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The company has a market capitalization of $362.30 billion, a P/E ratio of 9.37, a PEG ratio of 2.52 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company’s revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.68 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Institutional Trading of Johnson & Johnson

A number of hedge funds have recently added to or reduced their stakes in the stock. Christopher J. Hasenberg Inc bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $31,000. Keener Financial Planning LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $40,000. WFA Asset Management Corp increased its position in shares of Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson in the fourth quarter worth about $44,000. Finally, Disciplined Equity Management Inc. purchased a new stake in Johnson & Johnson in the fourth quarter worth $45,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.